Relevant data were compiled and organized based on compound class, experimental model, dose/exposure, and PI3K/Akt-related molecular readouts.<h4>Results and discussion</h4>This review highlights the potential of SSs to target the PI3K/Akt pathway and combat cancer progression, and addresses the limitations of conventional therapies in overcoming therapeutic resistance. Here, AKT1 is linked to cancer.